| |
James Kramer joins Bioreliance
James J. Kramer, Ph.D, joins BioReliance as Vice President of
Operations, U.S. Biologics. In his new position, Dr. Kramer is the US
Biologic Services Value Stream leader for the company and has direct
ownership for Program Management, Quality, GMP-Cell Banking, Clearance
Services, Molecular Biology, Cell Biology Microbiology, Virology,
In-Vivo Studies, Support Services and Facilities.
Click here to read the
press release.
BioReliance Corporation Launches iNet™ for Online Results Tracking of Biological Safety Tests
BioReliance is pleased to announce to US customers the release of iNet, a proprietary information technology system for submitting and
tracking test article details via a controlled and secure Internet access from any location worldwide. Now you can view the status of
current and past studies, keep in formed of when testing will be completed, download reports, and allow your colleagues to view the
status of your tests. Click here to read the press release.
|
|
|
|
|
BioReliance works with clients to provide customized solutions for innovative therapeutic products .
|
These products often require careful risk assessment as they are often derived from human or animal materials, with little or no purification. BioReliance’s experience in the design of testing and validation strategies will ensure that your product development stays on course.
BioReliance has taken a leading role internationally in the formulation of virological testing guidelines for this field. The health monitoring of the transgenics animals and the routine testing of the product are two areas where BioReliance can provide technical expertise.
BioReliance has worked with many of the world’s major pharmaceutical companies, supporting them through the development of their product. In addition to the extensive range of toxicology services offered to the pharmaceutical industry, BioReliance can also offer other testing programs, such as lot release.
|  |
|
|
